Traws Pharma (NASDAQ:TRAW) Announces Earnings Results

Traws Pharma (NASDAQ:TRAW) issued its earnings results on Monday. The company reported $95.66 earnings per share for the quarter, topping the consensus estimate of ($7.00) by $102.66, Zacks reports.

Traws Pharma Price Performance

NASDAQ TRAW traded down $0.02 on Monday, reaching $2.38. 8,167 shares of the company were exchanged, compared to its average volume of 155,783. Traws Pharma has a fifty-two week low of $2.02 and a fifty-two week high of $24.75. The company has a market cap of $8.69 million, a PE ratio of -0.02 and a beta of 1.42. The firm has a fifty day simple moving average of $4.73.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.